BioSpace News Archive

Results from several studies of Eli Lilly and Company’s investigational dual GIP and GLP-1 receptor agonist, tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes.

Cumulative three-year incidence rate of type 2 diabetes drops to 4%, according to PREVIEW intervention study presented at the ADA’s Scientific Sessions

Abbott announced new data showing use of its FreeStyle Libre system, the company’s revolutionary continuous glucose monitoring technology, significantly reduced hemoglobin A1c levels for people living with Type 2 diabetes on intensive insulin therapy.

The American Diabetes Association’s 79th Scientific Sessions, Ascensia Diabetes Care, a global leader in diabetes care, has presented clinical research that demonstrates that people with type 2 diabetes who participated in the study significantly lowered HbA1c while using its investigational Interconnected Diabetes Management Solution, suggesting it has the potential to improve self-care and glycemic control.

A new set of statistically significant overall survival (OS) data unveiled at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract# LBA1008), and published in The New England Journal of Medicine, are being heralded as a major breakthrough for pre- and perimenopausal women with hormone receptor positive

Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza®

43 experts from around the globe create the International Consensus on Time-in-Range (TIR) with clinical CGM targets to supplement the currently agreed-upon metrics for CGM-derived times in glucose ranges

One Drop launches 8-hour blood glucose forecasts, expanding upon the company’s AI-powered Automated Decision Support and making One Drop the first and only provider of blood glucose forecasts for people with type 2 diabetes

Dance Biopharm Holdings, Inc. presented Phase 2 Samba 04 clinical trial results for its inhaled preservative-free human insulin, Dance 501, for the treatment of type 2 diabetes.

TODAY2 study data show more intensive management and monitoring required, according to research presented at ADA’s Scientific Sessions